Skip to content
ClinCalc Pro
Menu
Antidotes & Toxicology

Dimercaprol

Brand names: BAL — British Anti-Lewisite

Dimercaprol (British anti-Lewisite) is a chelating agent used in the treatment of poisoning with certain heavy metals, including arsenic, mercury and lead.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Its sulfhydryl groups bind heavy-metal ions to form stable complexes that are then excreted, reducing the metal available to inhibit cellular enzymes.

Prescribing in practice

  • Avoid in iron, cadmium and selenium poisoning, where the resulting complexes are more toxic than the metal alone.
  • Use with caution in hepatic impairment and in patients with glucose-6-phosphate dehydrogenase deficiency owing to the risk of haemolysis.
  • It is given by deep intramuscular injection and commonly causes injection-site and systemic reactions.

Monitoring

Monitor blood pressure, heart rate, renal function and the patient's clinical response throughout treatment.

Counselling the patient

  • Warn that injections may be painful and can cause flushing, nausea or a burning sensation.
  • Explain that an alkaline urine may be encouraged to protect the kidneys, as advised by toxicology services.
  • Advise reporting any worsening symptoms promptly.

Evidence & guidelines

Dimercaprol is an established chelator for arsenic, inorganic mercury and lead poisoning, with use directed by poisons information services.

Reference: NPIS Toxbase; WHO Model Formulary; Clinical Toxicology 2004; 42(4):347-357; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

Dimercaprol is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.